Results 171 to 180 of about 326,926 (265)

MAFLD is linked to lower HBV DNA levels in chronic hepatitis B: clinical and transcriptomic insights. [PDF]

Front Med (Lausanne)
Gao X, Du X.
europepmc   +1 more source

Diagnostic Usefulness of Cell Block Samples in Fluid Overload‐Associated Large B‐Cell Lymphoma

Diagnostic Cytopathology, EarlyView.
ABSTRACT Fluid overload‐associated B‐cell lymphoma (FO‐LBCL) is a B‐cell neoplasm that presents as serous effusions without detectable tumor masses and Kaposi sarcoma‐associated herpesvirus (KSHV)/human herpesvirus 8 (HHV8) infection. Here, we report a case of an 81‐year‐old female patient with FO‐LBCL (Stage IVA) who presented with pericardial and ...
Hiroyuki Okanishi, Hiroko Kuwabara, Hiroko Nakayama, Mayo Odaka, Kozue Ariga, Isako Kataoka, Mari Tomiuka, Mayumi Uragami, Chihiro Deguchi, Shizuka Ono, Reika Takeda, Yoshitaka Kurisu, Yoshinobu Hirose, Yuuki Kinoshita, Taiji Yokote   +14 more
wiley   +1 more source

A bibliometric analysis of immunotherapy for chronic hepatitis B: trends and hotspots prediction. [PDF]

Front Immunol
Jin X, Tang Y, Ma Y, Li M, Gao Y.
europepmc   +1 more source

First Occurrence of Fatal Intoxication Involving Methiodone (IC‐26) in Finland; a Medicolegal Autopsy Case Report

Drug Testing and Analysis, EarlyView.
ABSTRACT Methiodone (IC‐26) is a non‐fentanyl novel synthetic opioid which has recently been detected in drug seizures in Europe. There is still limited data about the drug in published toxicological case work, both in non‐fatal and fatal cases. We present a medicolegal autopsy case report on a fatal intoxication in an individual undergoing opioid ...
Lasse Pakanen, Raimo A. Ketola, Pirkko Kriikku   +2 more
wiley   +1 more source

Diagnosing and defining MASLD in people living with chronic hepatitis B. [PDF]

Commun Med (Lond)
Martyn E, Arenas-Pinto A, Gilson R, Chandiwana N, Flanagan S, MacDonald D, Tsochatzis EA, Venter WDF, Manne-Goehler J, Matthews PC.   +9 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Development and Validation of a Social Influence Scale for Antiviral Therapy Behavior of Patients with Chronic Hepatitis B. [PDF]

Risk Manag Healthc Policy
Chen Y, Zhang Z, Jiang J, Wu S, Liu W.
europepmc   +1 more source

Economic burden and cost determinants of epilepsy in Georgia: A longitudinal cost‐of‐illness study

Epilepsia Open, EarlyView.
Abstract Objective To assess the economic burden, cost components, and individual‐level determinants of outpatient epilepsy care in adults in Georgia. Methods This longitudinal study of epilepsy‐related costs in adults with active epilepsy attending a tertiary epilepsy centre in Tbilisi collected clinical and sociodemographic data over 6 months. Direct
Sofia Kasradze, Tamar Jishkariani, Eka Burkadze, Ketevan Mamasakhlisi, Marika Megrelishvili, Josemir W. Sander   +5 more
wiley   +1 more source

Pradefovir mesylate and tenofovir amibufenamide for chronic hepatitis B: a systematic review and pragmatic treatment algorithm. [PDF]

Front Pharmacol
Yang S, Zhan L, Wan Z, Yu X.
europepmc   +1 more source

A PD‐L1 Nanobody‐Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC‐I

Exploration, EarlyView.
A PD‐L1 nanobody‐engineered synthetic RNA virus (αPDL1‐VLPs/shPCSK9) is fabricated to inhibit PCSK9 and upregulate MHC‐I to facilitate T cells recognition of hepatocellular carcinoma (HCC). Moreover, αPDL1‐VLPs/shPCSK9 can recognize PD‐L1 and block the PD‐1/PD‐L1 pathway to prevent immune evasion, while promoting M2‐to‐M1 macrophages polarization ...
Chuyu Huang, Yun Ye, Yi Guo, Guozheng Liao, Linyi Luo, Lingwen Ding, Yingling Miao, Linping Zhao, Yongchang Ouyang, Shiying Li   +9 more
wiley   +1 more source